Patent 9597340 was granted and assigned to Arena Pharmaceuticals on March, 2017 by the United States Patent and Trademark Office.
Provided are certain methods useful in the treatment of cancer comprising administering a compound of Formula Ia and pharmaceutical compositions thereof that modulate the activity of the cannabinoid CB2 receptor;